Summary
Thirty-two eligible patients with advanced metastatic breast cancer who had received no more than 1 prior chemotherapy regimen for metastatic disease (16 had received prior doxorubicin) were treated with piroxantrone at a dose of 120 mg/m2 intravenously every 21 days. In the twenty-seven patients evaluable for response, two partial responses were seen. Toxicities observed were primarily hematologic with grade 3 or greater granulocytopenia occurring in 34% of the patients. One patient developed symptomatic congestive heart failure at a total cumulative dose of 960 mg/m2. We conclude that piroxantrone given at this dose and schedule has minimal activity in patients with metastatic breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. Ca: a Cancer Journal for Clinicians 44(1):7–26, 1994
Friedman MA: New directions for breast cancer therapeutic research. Hematology — Oncology Clinics of North America 8(1):113–119, 1994
Showalter H, Johnson J, Werbel L, Leopold W, Jackson RC, Elslager E: 5-[(aminoakyl) amino] substituted antra [1,9-cd] pyrazol-6(2H)-ones as novel anticancer agents, synthesis and biological evaluations. J Med Chem 27:253–255, 1984
Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents against murine tumors. Cancer Res 45:5532–5539, 1985
Burchenal J, Pancoast T, Elslayer E: Anthrapyrazole and amsacrine analogues in mouse and human leukemiain vitro andin vivo (abstract). Proc Annu Meet Am Assoc Cancer Res 26:339, 1985
Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of Piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990
Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG: Phase I and clinical pharmacological evaluation of Piroxantrone hydrochloride (Oxantrazole). Cancer Res 50:3905–3909, 1990
Savarese DM, Denicoff AM, Berg SL, Hillig M, Baker SP, O'Shaughnessy JA, Chow C, Otterson GA, Balis FM, Poplack DG: Phase I study of high-dose Piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 9:1795–1803, 1993
Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and Piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85:388–394, 1993
Williamson SK, Crowley JJ, Livingston R, Hantel A, Doroshow JH: Phase II trial of Piroxantrone in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study. Invest New Drugs 10:29–30, 1992
Allen A, Wolf M, Crawford ED, Davis MP, Natale RB, Barnett ML: Phase II evaluation of Piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study. Invest New Drugs 10:129–132, 1992
Jenkins TR, Tangen C, MacDonald JS, Weiss G, Chadman R, Hantel A: A Phase II trial of Piroxantrone in adenocarcinoma of the pancreas: A Southwest Oncology Group Study. Invest New Drugs 11:329–331, 1993
Ingle JN, Kuross JA, Maillard JA, Loprinzi CL, Jung SH: Evaluation of piroxantrone in women with metastatic breast cancer and failure on non-anthracycline related chemotherapy: A North Central Cancer Treatment Group Trial. Proc Annu Meet Am Soc Clin Oncol 12:A140, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ravdin, P.M., Green, S., Doroshow, J.H. et al. Phase II trial of piroxantrone in metastatic breast cancer. Invest New Drugs 12, 333–336 (1994). https://doi.org/10.1007/BF00873050
Issue Date:
DOI: https://doi.org/10.1007/BF00873050